CRISPR Gene Edit Detection Assay

A cost-effective screening solution to detect CRISPR and other gene edits.

DETAILED PRODUCT DESCRIPTION

  • Employs allele-specific primers to distinguish wild-type from edited sequences with precision.
  • Uses simple, unlabelled primers customized to specific target sequences.
  • Assemble the reaction using ready-to-use PACE Assays and PACE Genotyping Master Mix.
  • Scalable, and rapid alternative for primary screening of genome edits, applicable to both agricultural and life sciences research.

REQUIREMENTS

  • PACE Genotyping Master Mix (or PACE 2.0 Genotyping Master Mix)
  • qPCR machine or Thermocycler + Fluorescent plate reader
  • PCR plates with optically clear seals
  • Template DNA
  • PCR-grade water

APPLICATIONS AND BENEFITS

  • Accurate, quick, cost-effective
  • Reduces reliance on sequencing by allowing large-scale pre-screening.
  • Compatible with plants, animals, tissue cultures, protoplasts, seeds, and more.
  • Detects a wide range of edits, including SNPs, knockouts, and both small and large Indels.

3CR END-TO END SOLUTIONS

About

Custom assays to detect the presence of your target edit—whether introduced through directed editing or Non-Homologous End Joining (NHEJ)—designed using DNA sequences submitted by you, including the target site, spacer, and PAM. Assay information is submitted via the provided template and guidelines.

While high-throughput sequencing remains a common approach for screening, it is often time-consuming, costly, and data-intensive. PACE® (PCR Allele Competitive Extension) genotyping offers a rapid, scalable, and cost-effective alternative for primary screening of genome edits, widely applicable in both agricultural and life sciences research.

Confidentiality Assured: Assay primers are proprietary to each client. Each order includes 400 µL of ready-to-use 72x PACE assay, enough for at least 2,800 reactions at a 10 µL volume.

How does it work?

The PACE CRISPR Gene Edit Detection Assay uses competitive allele-specific PCR with fluorescent reporting to distinguish between wild-type and edited sequences. Custom-designed primers target the site of edit, allowing precise detection of base substitutions, knockouts, small indels, or SNPs introduced via CRISPR editing – whether the resultant edits are known or unknown.

 

PACE CRISPR GENE EDIT DETECTION WORKFLOW

  1. Assay Design: Submit the target sequence to 3CR Bioscience, including 100 bases upstream and downstream following the submission guidelines.
  2. Assay Delivery: Receive ready-to-use PACE CRISPR gene edit detection assays, pre-validated using synthetic controls tailored to detect your specific edits or wild-type sequences.
  3. Reaction Setup: Assemble the reaction using the ready-to-use PACE Assays and PACE Genotyping Master Mix.
  4. Run and Analyze: Perform the PCR run, analyze fluorescence data, and identify edited samples.
  5. Follow-Up: Isolate positive samples for further characterization by sequencing, if required.

FAQ:

Can the CRISPR assay detect edits created by both NHEJ and HDR?

Yes, PACE can identify mutations resulting from either NHEJ (random indels) or HDR (precise template-based edits).

How does this compare to high-throughput sequencing?

PACE is faster, cheaper, and easier to scale for initial screens. Sequencing remains valuable for final validation, but PACE is ideal for early-stage or bulk population screening.

How many reactions does one assay cover?

Each 400 µL aliquot is sufficient for at least 2,800 reactions at a standard 10 µL volume.

Is the assay available as a validated service?

Yes. You can choose to receive the unvalidated assay for in-house use or send us your DNA samples for validation before shipment.

What is the turnaround time?

From PCR setup to results, the process typically takes 2–4 hours. Assay design and shipping timelines vary based on validation and synthesis steps.

What sample types can I use?

Any DNA source—including crude lysates from cells, seeds, leaf tissue, or microbes—is compatible.

What types of edits can PACE detect?

PACE detects a wide range of edits: single-nucleotide changes (SDN1), small and large insertions/deletions (SDN2/3), gene knockouts, and rearrangements. It can also monitor for off-target effects.

[fibosearch]
Name(Required)
This field is for validation purposes and should be left unchanged.

Contact us

MEET OUR TEAM

Steve Asquith Managing Director
Steve began his career in the Genetics Division of GlaxoSmithKline, as part of the team establishing GSK’s high-throughput core genotyping laboratory. Steve joined KBioscience when it was first founded in 2002 and was a key driver in taking the company from a small start-up to a multi-national service laboratory, quickly growing the company’s revenue to over $7.5M p.a. Following the acquisition of Kbioscience by LGC in 2011, Steve was appointed Global Director of Operations for LGC Genomics, responsible for over 100 staff in Europe and N. America, successfully elevating the genotyping products and service business. Steve held a crucial leadership role until he left in 2016. In 2017 Steve joined forces with John Holme to create 3CR Bioscience, a new company with a mission to deliver outstanding, customer-focused genotyping products with innovation and affordability at its core.
Dr. John Holme Technical Director
John joined KBioscience shortly after it was founded, in 2003, and became Head of Technical Development, building the company’s genotyping and DNA extraction product portfolio and service delivery until 2011 when it was acquired by LGC. Post-acquisition, John was appointed Head of Technical Group for LGC Genomics, in charge of all Research & Development and Technical Support activities for the company. In this role John continued to build on the high-quality products and services provided to the companies growing customer base. During the 19 years John has worked in commercial R&D, he has co-invented numerous highly successful products including PACE®, ProbeSure, KASP™, KlearKall, KlearGene, KlearAmp and KlearTaq™, creating breakthrough offerings in genotyping and extraction and generating huge revenues for the companies he has worked in. In 2017, he joined forces with Steve Asquith and started 3CR Bioscience. John is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Dr. Nisha JainOperations Director
Nisha has been innovating since the start of her career at Geneform Technologies developing Iso-thermal Genotyping Technologies. Nisha joined KBioscience in 2008, as Senior R&D Scientist and key account Technical Support Scientist, developing KASP and Klearkall performance and coinventing two further versions of KASP. Nisha has more than 15 years’ experience working in molecular biology and genotyping technologies, with extensive experience in the areas of R&D, Quality Assurance and Customer Technical Support. She has technically assisted many giants of the industry with their protocol development and troubleshooting and continues to deliver high-quality support and guidance. In 2018, Nisha joined 3CR Bioscience as Operations Director where she continues to develop PACE and ProbeSure for an increasing range of applications, and to grow 3CR Bioscience’s new product pipeline. Nisha is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Nazma Saffin General Manager
For 20 years Nazma Saffin has worked and gained extensive expertise within the genotyping sector. Working at Kbioscience and then LGC, she has held operational leadership posts responsible for manufacturing and laboratory services. With experience of ISO 9001 implementation, production scale up and LEAN operations, Nazma has successfully led highly profitable production departments. Joining 3CR Bioscience in 2022, Nazma is committed to delivering operational excellence.
Jon Curtis Non-Executive Chair
After 8 years in The Royal Air Force, Jon moved to the Imperial Cancer Research Fund where he pioneered the use of ultra high-throughput genomic automation, capable of 46,000 PCRs per hour. In the 1990’s Jon joined GlaxoSmithKline, implementing a high-throughput genomics platform into their drug discovery pipeline. Whilst there he also developed acoustic mixing into compound management, becoming the gold standard across pharma. Jon developed the world’s first commercially viable 1536-well PCR plates, automated thermal & laser plate-sealer, plus automated liquid-handling & tip washing tools to reduce waste and costs. In 2002 Jon co-founded KBioscience with Phil Robinson, utilising ultra high-throughput PCR instrumentation & a suite of automation tools to create the company’s SNPline robotic platform, with a capacity of 250,000 PCRs/day. The business was underpinned by their ground-breaking patented genotyping chemistry, KASP™, which has over 10,000 scientific papers to date. In November 2022 Jon joined 3CR Bioscience acting as an advisor bringing his commercial and scientific experience to the company.